A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

Recruiting now · Phase 1/Phase 2

Conditions studied: Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Gastric Cancer/Gastroesophageal Junction Cancer, High Grade Serous Ovarian Carcinoma

In brief

Key facts

Study ID: NCT07115043
Run by: AstraZeneca
People needed: 60
Starts: 2025-07-29
Expected to finish: 2029-10-02
Last updated by the study team: 2026-07-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Participant ≥ 18 year
ECOG PS of 0 to 1
Provision of 'archival' tumor specimen
At least one measurable lesion according to RECIST v1.1,
Minimum life expectancy of 12 weeks
Adequate and stable cardiac function
Adequate bone marrow, liver and kidney function
Body weight ≥ 35 kg
Capable of giving signed informed consent
Module 1 specific inclusion criteria:
Participants with locally advanced or metastatic select solid tumors (MM, Squamous cell carcinoma of skin, MCC, NSCLC, Head and neck squamous cell carcinoma, Gastric cancer/gastroesophaegeal junction cancer, RCC, HGSOC, Triple negative breast cancer) who have received adequate SoC
Module 2 specific inclusion criteria:
Participants with Stage IV NSCLC Dose Escalation/Backfills
Have received at least one prior regimen in metastatic setting (2L+ NSCLC). Participants with actionable tumor alterations should have received targeted therapy if locally available OR
Have not received systemic therapy (1L NSCLC) and have PD-L1 expression ≥ 1%.
Dose Expansion
Have not received systemic therapy (1L NSCLC) and have PD-L1 expression ≥ 1%.

You may not qualify if…

Any evidence of:
Severe or uncontrolled systemic diseases including respiratory, cardiac or tumor-related conditions
History or planned organ or allogeneic stem cell transplantation.
Active or prior documented autoimmune or inflammatory disorders, within the past 3 years
Any prior toxicities that led to permanent discontinuation of prior immunotherapy
Persistent toxicities (CTCAE Grade ≥ 2) caused by previous anti-cancer therapy
Brain metastases unless treated, asymptomatic, stable, and not requiring continuous corticosteroids
Acute untreated or symptomatic malignant spinal cord compression, or a history of leptomeningeal carcinomatosis.
Active uncontrolled or chronic infection of hepatitis B, hepatitis C
Prior history of Grade ≥ 3 non-infectious pneumonitis.
Participant requires chronic immunosuppressive therapy (including steroids > 10 mg prednisone/day or equivalent).
Receipt of live attenuated vaccine within 30 days.
Module 2 specific exclusion criteria:
Previous treatment with anti-TIGIT therapy
1L NSCLC participants with genetic alteration such as EGFR that has a targeted therapy in 1L as per local SoC

Where it is running

Research Site — Grand Rapids, Michigan, United States (enrolling)
Research Site — St Louis, Missouri, United States (enrolling)
Research Site — Pittsburgh, Pennsylvania, United States (enrolling)
Research Site — Houston, Texas, United States (enrolling)
Research Site — San Antonio, Texas, United States (enrolling)
Research Site — Fairfax, Virginia, United States (enrolling)
Research Site — East Melbourne, Australia (enrolling)
Research Site — Chūōku, Japan (enrolling)
Research Site — Kashiwa, Japan (enrolling)
Research Site — Seoul, South Korea (enrolling)
Research Site — Seoul, South Korea (enrolling)
Research Site — Seoul, South Korea
Research Site — Seoul, South Korea

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.